Composition : Gefitinib IP 250 mg Tablet
Dosage Form : Tablet
Packaging Type : Blister
Packaging : 10*10
Price : ₹1/-
Please Contact For Best Price
GEFISOL 250 Tablet (Gefitinib IP 250 mg) is a crucial oral oncological medicine, belonging to the class of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). It is specifically indicated as first-line therapy for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors harbor specific EGFR-TK activating mutations (such as exon 19 deletions or L858R substitution).
The drug works by blocking the intracellular phosphorylation required for tumor cell survival and proliferation, thereby interfering with the growth and spread of cancer cells. As a highly selective targeted agent, Gefitinib offers significant improvements in progression-free survival (PFS) and a more favorable tolerability profile compared to traditional chemotherapy in mutation-positive patients.
The market for targeted cancer therapies is growing exponentially, driven by rising NSCLC incidence and mandatory genetic screening. Securing the distribution rights for a specialized, high-cost medicine like GEFISOL 250 positions you at the forefront of the profitable Oncology segment. We offer an exclusive PCD Pharma Franchise opportunity with complete Monopoly Rights in your territory. Partner with us for a high-value product, ethical business practices, assured stock availability, and dedicated promotional support targeting oncologists and specialty hospitals.
Read More